"Primary" and "secondary" muscle-invasive bladder cancer is more than just a surrogate for molecular subtypes.

"Conflicts of Interest: EJ Pietzak: Scientific Advisory Board: Merck; Consultant: Chugai Pharma. H Al-Ahmadie: Consultant: Bristol-Myers-Squibb, AstraZeneca, EMD Ser-ono. DF Bajorin: Honoraria from the speaker’s bureau of Merck; Consultant/advisory board: Merck, Pfizer, Bristol-Myers Squibb, Urogen, Genentech,Eli Lilly. JE Rosenberg: Stock and Other Ownership Interests: Merck, Illumina; Honoraria: UpToDate, Bristol-Myers Squibb, AstraZeneca, Medscape, Vindico, Peerview, Chugai Pharma; Consulting or Advisory Role: Lilly, Merck, Agensys, Roche/Genentech, Sanofi, AstraZeneca/MedImmune, Bristol-Myers Squibb, EMD Serono, Seattle Genetic, Bayer, InovioPharmaceuticals, BioClin Therapeutics, QED Therapeutic, Adicet Bio,Sensei Biotherapeutics; Patents, Royalties, Other Intellectual Property: Predictor of platinum sensitivity; Research Funding: Genentech, Oncogenex, Agensys, Mirati Therapeutics, Novartis, Viralytics, Genen-tech/Roche, Incyte, Seattle Genetics, Bayer; Travel, Accommodations, Expenses: Genentech/Roche, Bristol-Myers Squibb. BH Bochner: Chair of data safety monitoring committee: Genentech; CourseInstructor: Olympus. DB Solit: Consultant for Pfizer, Loxo Oncology and Illumina. G Iyer: Consultant: Bayer."

"Funding: This work was supported by the Sidney Kimmel Center for Prostate and Urologic Cancers , the Michael and Zena Wiener for Therapeutics Program in Bladder Cancer, Pin Down Bladder Cancer, Cycle for Survival , the Marie-Josee and Henry R. Kravis Center for Molecular Oncology , NIH/NCATS Grant Number UL1-TR002384 , the National Cancer Institute Cancer Center Core Grant Number P30-CA008748 , MSKCC SPORE in Bladder Cancer P50- CA221745 , NIH/NCI K12 Paul Calabresi Career Development Award for Clinical Oncology ( K12 CA184746 )."